The Nordic IBD treatment strategy trial (NORDTREAT)
| Reference number | |
| Coordinator | Örebro universitet - Inst för Medicinska Vetenskaper |
| Funding from Vinnova | SEK 12 529 280 |
| Project duration | September 2019 - September 2025 |
| Status | Completed |
| Venture | Nordic collaboration in health |
Important results from the project
The project has achieved its goals and resulted in one of the largest clinical trials for patients with newly diagnosed inflammatory bowel disease (IBD), with over 300 patients enrolled within six weeks of diagnosis. The results of the trial are expected to be presented in 2026. In addition, new biomarkers have been analysed in collaboration with industry partners, with findings published as scientific papers and doctoral theses. A strong Nordic research collaboration has been established.
Expected long term effects
The project is expected to contribute to improved treatment strategies for inflammatory bowel disease (IBD), enabling early identification of patients at increased risk of a severe disease course. The established Nordic collaboration between academia, healthcare, industry, and patient organisations is expected to strengthen future research, innovation, and patient benefit. Moreover, it has the potential to position the Nordics at the forefront of precision medicine in IBD.
Approach and implementation
The project brought together researchers, clinicians, patients, and industry partners in Denmark, Iceland, Norway, and Sweden. A randomized clinical trial was conducted in parallel with the initiation of a prospective observational cohort study and analyses of previously biobanked samples from existing Nordic cohorts. Protocols for data collection and biobanking were harmonized to facilitate analyses and continued research collaboration.